Gene · 2217
Papers4,523
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 4,523
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Aseptic Meningitis Following Rozanolixizumab in a Patient With Refractory Anti-MuSK Positive Myasthenia Gravis: A Case Report. | Neurohospitalist | 2026 | 40949001 | PubTator, text mining | PubMed |
| Endocytotic Albumin Uptake Pathways in Human Adipose Stem Cells and Connection to Intracellular Calcium Oscillations and the Neonatal Fc receptor. | Cells Tissues Organs | 2026 | 40239638 | PubTator, text mining | PubMed |
| Bioengineered milk-derived extracellular vesicles implementing high drug loading and membrane integrity for efficient oral drug delivery. | Asian J Pharm Sci | 2025 | 41809257 | PubTator, text mining | PubMed |
| Unlocking binding properties of single-domain antibodies targeting the polymeric immunoglobulin receptor to enhance mucosal enrichment of IgG against respiratory syncytial virus. | Front Immunol | 2025 | 41737496 | PubTator, text mining | PubMed |
| Dulaglutide and pregnancy: a comprehensive safety assessment using the ex vivo placenta perfusion and in vitro models. | Front Pharmacol | 2025 | 41640683 | PubTator, text mining | PubMed |
| VIF-Ig: a novel fc framework for ADCC by incorporation of VHH unit. | Protein Eng Des Sel | 2025 | 41593815 | PubTator, text mining | PubMed |
Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study). | Front Med (Lausanne) | 2025 | 41551508 | PubTator, text mining | PubMed |
| Pharmacokinetic and Pharmacodynamic Modeling of Antibody-Drug Conjugates. | Cancers (Basel) | 2025 | 41514518 | PubTator, text mining | PubMed |
| Does the Chimerization Process Affect the Immunochemical Properties of WNV-Neutralizing Antibody 900? | Int J Mol Sci | 2025 | 41465606 | PubTator, text mining | PubMed |
| Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. | Biomedicines | 2025 | 41462987 | PubTator, text mining | PubMed |
| Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes. | Cureus | 2025 | 41458822 | PubTator, text mining | PubMed |
| Functionalized albumin nanoparticles: A multifunctional platform for enhanced brain drug delivery. | Mater Today Bio | 2025 | 41445782 | PubTator, text mining | PubMed |
| Temporal dynamics of IgG-mediated immunometabolic dysfunction: from acute obesity to chronic aging. | Front Immunol | 2025 | 41425575 | PubTator, text mining | PubMed |
| Human C. difficile-specific memory B cells encode protective IgG1 despite predominance of non-neutralizing antibodies. | bioRxiv | 2025 | 41415461 | PubTator, text mining | PubMed |
| Nipocalimab-aahu in generalised myasthenia gravis: A new Fc receptor-targeted option for antibody-positive patients. | Ibrain | 2025 | 41395452 | PubTator, text mining | PubMed |
| Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases. | Ther Adv Neurol Disord | 2025 | 41394285 | PubTator, text mining | PubMed |
| Structural hijacking of FcRn by human astrovirus spikes reveals conserved epitopes for broad-spectrum antivirals. | Cell Rep | 2025 | 41389202 | PubTator, text mining | PubMed |
| Genetic insights into colorectal cancer pathogenesis: a multi-omics and immunity perspective. | Transl Cancer Res | 2025 | 41378022 | PubTator, text mining | PubMed |
| Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy. | Int J Mol Sci | 2025 | 41373880 | PubTator, text mining | PubMed |
| Chimeras co-targeting antigens and FcγRIIb trigger degradation of extracellular soluble proteins and pathological aggregates. | Nat Commun | 2025 | 41372196 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2217/papers?page=13